NCT00403130

Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer

Phase II Open Label Study of Gemcitabine, Paclitaxel and Bevacizumab Combination as First Line Treatment for Metastatic Breast Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: George Albert Fisher · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Single-institution phase 2 trial investigating the efficacy of capecitabine, oxaliplatin and bevacizumab for patients with metastatic neuroendocrine tumors.

Detailed description

This study will evaluate the time-to-progression (TTP) in patients with metastatic breast cancer, receiving 1st line therapy with bevacizumab in combination with paclitaxel and gemcitabine. Secondary objectives will include response rates and overall survival (OS).

Conditions

• Breast Cancer
• Metastatic Breast Cancer

Interventions

Type	Name	Description
DRUG	Gemcitabine	Gemcitabine 1000 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
DRUG	Paclitaxel	Paclitaxel 80 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
DRUG	Bevacizumab	Bevacizumab 10 mg/kg by IV infusion, days 1 and 15 in 28-day cycles

Timeline

• Start date: 2006-02-01
• Primary completion: 2010-09-01
• Completion: 2012-11-01
• First posted: 2006-11-23
• Last updated: 2019-02-20
• Results posted: 2017-03-24

Locations

1 site across 1 country: United States